Clinical trial
Dexamethasone Followed by Denileukin Diftitox in Treating Patients With…
NCT00006345 · Ligand Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00006345 |
|---|---|
| Title | Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma |
| Official title | An Evaluation of Corticosteroid Pretreatment in Cutaneous T-Cell Lymphoma Patients Receiving Ontak (Denileukin Difitox) |
| Lead sponsor | Ligand Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Drug/Agent Toxicity by Tissue/Organ, Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | denileukin diftitox, dexamethasone |
| Start date | Nov 1, 1999 |
| Completion | Mar 1, 2004 |
| First posted | Mar 25, 2004 |
| Last update posted | May 30, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: